Fsy-bearing PD-1 reacted andtrapped PD-L1 in vitro; in tumor models in humanizedmice, this synthetic protein inhibited tumor growth to the same extentas the clinically approved anti-PD-L1 antibody atezolizumab, whichengages noncovalently. This evidence concerns the gene CD274 and neoplasm.